$STOK
Stoke Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023017839 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4
Revenue -$2.481M $5.152M $3.268M
YoY Change -176.79% 71.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.23M $10.21M $9.384M
YoY Change 1.18% 7.64% 7.57%
% of Gross Profit
Research & Development $20.55M $19.63M $21.06M
YoY Change 11.95% 7.22% 33.27%
% of Gross Profit
Depreciation & Amortization $611.0K $597.0K $609.0K
YoY Change 102.32% 141.7% 159.15%
% of Gross Profit
Operating Expenses $30.78M $29.84M $30.44M
YoY Change 8.12% 7.36% 24.13%
Operating Profit -$33.26M -$24.69M
YoY Change 31.79% -0.42%
Interest Expense $2.567M $2.103M $1.479M
YoY Change 371.88% 1922.12% 4008.33%
% of Operating Profit
Other Income/Expense, Net $2.608M $2.145M $42.00K
YoY Change 345.05% 1369.18% 0.0%
Pretax Income -$30.65M -$22.55M -$25.66M
YoY Change 24.35% -8.54% 4.94%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$30.65M -$22.55M -$25.66M
YoY Change 24.35% -8.54% 4.94%
Net Earnings / Revenue -437.6% -785.04%
Basic Earnings Per Share -$0.69 -$0.53
Diluted Earnings Per Share -$0.69 -$0.53 -$0.65
COMMON SHARES
Basic Shares Outstanding 44.19M 44.15M 39.43M
Diluted Shares Outstanding 44.19M 42.54M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $231.4M $253.7M $229.6M
YoY Change -16.03% -13.49% 4.45%
Cash & Equivalents $192.1M $190.3M $113.6M
Short-Term Investments $39.39M $63.33M $116.0M
Other Short-Term Assets $3.699M $5.880M $2.955M
YoY Change -71.93% -52.16% -68.14%
Inventory
Prepaid Expenses $10.95M $10.19M $10.93M
Receivables
Other Receivables
Total Short-Term Assets $246.2M $270.2M $244.1M
YoY Change -14.85% -11.62% 6.48%
LONG-TERM ASSETS
Property, Plant & Equipment $6.472M $6.789M $6.675M
YoY Change 10.29% -29.27% 61.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $569.0K $569.0K $569.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $10.69M $11.56M $12.00M
YoY Change -12.89% 13.7% 24.36%
TOTAL ASSETS
Total Short-Term Assets $246.2M $270.2M $244.1M
Total Long-Term Assets $10.69M $11.56M $12.00M
Total Assets $256.9M $281.8M $256.1M
YoY Change -14.77% -10.81% 7.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.556M $4.299M $766.0K
YoY Change -56.8% 29.18% -67.88%
Accrued Expenses $11.52M $13.27M $15.24M
YoY Change -9.03% 25.38% 7.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.84M $31.53M $31.39M
YoY Change -21.02% 37.64% 83.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.629M $2.303M $2.968M
YoY Change -61.64% -95.66% -24.84%
Total Long-Term Liabilities $44.89M $36.45M $39.82M
YoY Change -9.24% -31.3% 908.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.84M $31.53M $31.39M
Total Long-Term Liabilities $44.89M $36.45M $39.82M
Total Liabilities $66.72M $67.97M $71.22M
YoY Change -13.46% -10.51% 237.72%
SHAREHOLDERS EQUITY
Retained Earnings -$350.3M -$319.7M -$297.2M
YoY Change 42.78% 51.54%
Common Stock $4.000K $4.000K $4.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $190.2M $213.8M $184.8M
YoY Change
Total Liabilities & Shareholders Equity $256.9M $281.8M $256.1M
YoY Change -14.77% -10.81% 7.2%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$30.65M -$22.55M -$25.66M
YoY Change 24.35% -8.54% 4.94%
Depreciation, Depletion And Amortization $611.0K $597.0K $609.0K
YoY Change 102.32% 141.7% 159.15%
Cash From Operating Activities -$21.80M -$21.36M -$22.37M
YoY Change 9.39% -165.73% 37.61%
INVESTING ACTIVITIES
Capital Expenditures $839.0K $165.0K $409.0K
YoY Change -223.02% -80.38% -301.48%
Acquisitions
YoY Change
Other Investing Activities $24.31M $53.25M $22.90M
YoY Change 2836.23% -139.46% 90.83%
Cash From Investing Activities $23.47M $53.09M $22.49M
YoY Change 15977.4% -139.1% 90.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 48.00K 45.05M 43.00K
YoY Change -98.6% 5.99% -74.85%
NET CHANGE
Cash From Operating Activities -21.80M -21.36M -22.37M
Cash From Investing Activities 23.47M 53.09M 22.49M
Cash From Financing Activities 48.00K 45.05M 43.00K
Net Change In Cash 1.721M 76.78M 160.0K
YoY Change -110.52% -174.34% -103.73%
FREE CASH FLOW
Cash From Operating Activities -$21.80M -$21.36M -$22.37M
Capital Expenditures $839.0K $165.0K $409.0K
Free Cash Flow -$22.64M -$21.52M -$22.78M
YoY Change 17.63% -168.0% 41.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2023Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001623526
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38938
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Stoke Therapeutics, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1144582
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
45 Wiggins Ave
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bedford
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01730
CY2023Q1 dei City Area Code
CityAreaCode
781
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
430-8200
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
STOK
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44188534
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190339000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113556000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
63334000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
116039000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10191000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10932000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
5880000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2955000
CY2023Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
492000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
588000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
270236000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
244070000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
569000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
569000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4202000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4753000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6789000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6675000
CY2023Q1 us-gaap Assets
Assets
281796000
CY2022Q4 us-gaap Assets
Assets
256067000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4299000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
766000
CY2023Q1 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
13777000
CY2022Q4 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
15748000
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
13451000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14880000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
31527000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31394000
CY2023Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
34144000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
36856000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2303000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2968000
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
36447000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
39824000
CY2023Q1 us-gaap Liabilities
Liabilities
67974000
CY2022Q4 us-gaap Liabilities
Liabilities
71218000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44175089
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44175089
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39439575
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39439575
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
534111000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
483170000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-598000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1175000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-319695000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-297150000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
213822000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
184849000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
281796000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
256067000
CY2023Q1 us-gaap Revenues
Revenues
5152000
CY2022Q1 us-gaap Revenues
Revenues
3000000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19631000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18309000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10211000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9486000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
29842000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
27795000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24690000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24795000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2103000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
104000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2145000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
146000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22545000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24649000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42536474
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42536474
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37448301
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37448301
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22545000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24649000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
577000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-516000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
577000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-516000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21968000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25165000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
217777000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24649000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-516000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4975000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
93000
CY2022Q1 stok Shares Sold As Part Of Controlled Equity Offering Sales Agreement Value
SharesSoldAsPartOfControlledEquityOfferingSalesAgreementValue
42128000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
169000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
239977000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
184849000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22545000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
577000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5887000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
158000
CY2023Q1 stok Shares Sold As Part Of Controlled Equity Offering Sales Agreement Value
SharesSoldAsPartOfControlledEquityOfferingSalesAgreementValue
44743000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
153000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
213822000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-22545000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-24649000
CY2023Q1 us-gaap Depreciation
Depreciation
597000
CY2022Q1 us-gaap Depreciation
Depreciation
247000
CY2023Q1 stok Amortization And Accretion Of Marketable Securities
AmortizationAndAccretionOfMarketableSecurities
32000
CY2022Q1 stok Amortization And Accretion Of Marketable Securities
AmortizationAndAccretionOfMarketableSecurities
235000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5887000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4975000
CY2023Q1 stok Reduction In Carrying Amount Of Operating Lease Right Of Use Assets
ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets
550000
CY2022Q1 stok Reduction In Carrying Amount Of Operating Lease Right Of Use Assets
ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets
377000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2088000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3265000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
351000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3443000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4140000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
58014000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21356000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
32491000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
143941000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
165000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
841000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
53250000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
9000000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
53085000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-135782000
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
153000
CY2022Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
169000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
158000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
93000
CY2023Q1 stok Proceeds From Controlled Equity Offering Sales Agreement
ProceedsFromControlledEquityOfferingSalesAgreement
44743000
CY2022Q1 stok Proceeds From Controlled Equity Offering Sales Agreement
ProceedsFromControlledEquityOfferingSalesAgreement
42245000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45054000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42507000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
76783000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-60784000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
114125000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
145464000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
190908000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84680000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
545000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
301000
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
525000
CY2023Q1 stok Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
8356000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84111000
CY2022Q4 stok Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6601000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
569000
CY2023Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1529000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
569000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
190908000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84680000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5754000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
982000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and disclosure of contingent assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.</span></p>
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190339000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
63932000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
598000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
63334000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
117214000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1175000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
116039000
CY2023Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2404000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2359000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
506000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
509000
CY2023Q1 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
13777000
CY2022Q4 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
15748000
CY2018Q3 stok Area Of Space Subject To Operating Lease
AreaOfSpaceSubjectToOperatingLease
23000
CY2018Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2018Q3 stok Operating Lease Cost Per Year
OperatingLeaseCostPerYear
900000
CY2018Q3 stok Annual Base Rent Increase Percentage For Operating Lease
AnnualBaseRentIncreasePercentageForOperatingLease
0.03
CY2018Q3 stok Operating Lease Commencement Date
OperatingLeaseCommencementDate
2018-12-10
CY2018Q4 stok Area Of Space Subject To Operating Lease
AreaOfSpaceSubjectToOperatingLease
2485
CY2018Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2018Q4 stok Number Of Renewal Option To Extend Operating Lease Terms
NumberOfRenewalOptionToExtendOperatingLeaseTerms
1
CY2018Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2018Q4 stok Operating Lease Cost Per Year
OperatingLeaseCostPerYear
200000
CY2018Q4 stok Annual Base Rent Increase Percentage For Operating Lease
AnnualBaseRentIncreasePercentageForOperatingLease
0.025
CY2018Q4 stok Operating Lease Commencement Date
OperatingLeaseCommencementDate
2019-05-01
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1902000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2608000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
172000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4682000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
184000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
4498000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4202000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2404000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2094000
CY2023Q1 stok Operating Lease Liability Excluding Leases Entered Access Yet To Be Granted
OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted
4498000
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0469
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1188500
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
60100000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P3Y11M15D
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5887000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4975000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22545000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24649000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42536474
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42536474
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37448301
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37448301
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
stok-20230331_def.xml Edgar Link unprocessable
stok-20230331_cal.xml Edgar Link unprocessable
0000950170-23-017839-index-headers.html Edgar Link pending
0000950170-23-017839-index.html Edgar Link pending
0000950170-23-017839.txt Edgar Link pending
0000950170-23-017839-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img144415984_0.jpg Edgar Link pending
img144415984_1.jpg Edgar Link pending
img144415984_2.jpg Edgar Link pending
img144415984_3.jpg Edgar Link pending
img144415984_4.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stok-20230331.htm Edgar Link pending
stok-20230331.xsd Edgar Link pending
stok-ex31_1.htm Edgar Link pending
stok-20230331_pre.xml Edgar Link unprocessable
stok-20230331_lab.xml Edgar Link unprocessable
stok-20230331_htm.xml Edgar Link completed
stok-ex31_2.htm Edgar Link pending
stok-ex32_1.htm Edgar Link pending
stok-ex32_2.htm Edgar Link pending
stok-ex4_1.htm Edgar Link pending